Balancing the interplay of histone deacetylases and non-coding genomes: a step closer to understand the landscape of cancer treatment

Histone deacetylase (HDAC) inhibitors have enormous therapeutic potential as effective epigenetic regulators, and now with the focus on the selective HDAC6 inhibitor in ongoing clinical trials, more advantages over other non-selective pan-HDAC inhibitors are foreseeable. As it is of paramount import...

Descripción completa

Detalles Bibliográficos
Autores principales: Pu, Jingjing, Liu, Ting, Sharma, Amit, Schmidt-Wolf, Ingo G. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657130/
https://www.ncbi.nlm.nih.gov/pubmed/37978516
http://dx.doi.org/10.1186/s12920-023-01724-3
_version_ 1785148123271659520
author Pu, Jingjing
Liu, Ting
Sharma, Amit
Schmidt-Wolf, Ingo G. H.
author_facet Pu, Jingjing
Liu, Ting
Sharma, Amit
Schmidt-Wolf, Ingo G. H.
author_sort Pu, Jingjing
collection PubMed
description Histone deacetylase (HDAC) inhibitors have enormous therapeutic potential as effective epigenetic regulators, and now with the focus on the selective HDAC6 inhibitor in ongoing clinical trials, more advantages over other non-selective pan-HDAC inhibitors are foreseeable. As it is of paramount importance to understand the complex regulatory web of mutual interactions involving epigenetic machinery and non-coding genome in regulating gene expression, herein, we investigated the intriguing interactions between HDAC6-induced lncRNA (LINC00152) and its possible sponge miRNA (hsa-miR-499a-5p) in multiple myeloma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12920-023-01724-3.
format Online
Article
Text
id pubmed-10657130
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106571302023-11-17 Balancing the interplay of histone deacetylases and non-coding genomes: a step closer to understand the landscape of cancer treatment Pu, Jingjing Liu, Ting Sharma, Amit Schmidt-Wolf, Ingo G. H. BMC Med Genomics Comment Histone deacetylase (HDAC) inhibitors have enormous therapeutic potential as effective epigenetic regulators, and now with the focus on the selective HDAC6 inhibitor in ongoing clinical trials, more advantages over other non-selective pan-HDAC inhibitors are foreseeable. As it is of paramount importance to understand the complex regulatory web of mutual interactions involving epigenetic machinery and non-coding genome in regulating gene expression, herein, we investigated the intriguing interactions between HDAC6-induced lncRNA (LINC00152) and its possible sponge miRNA (hsa-miR-499a-5p) in multiple myeloma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12920-023-01724-3. BioMed Central 2023-11-17 /pmc/articles/PMC10657130/ /pubmed/37978516 http://dx.doi.org/10.1186/s12920-023-01724-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Comment
Pu, Jingjing
Liu, Ting
Sharma, Amit
Schmidt-Wolf, Ingo G. H.
Balancing the interplay of histone deacetylases and non-coding genomes: a step closer to understand the landscape of cancer treatment
title Balancing the interplay of histone deacetylases and non-coding genomes: a step closer to understand the landscape of cancer treatment
title_full Balancing the interplay of histone deacetylases and non-coding genomes: a step closer to understand the landscape of cancer treatment
title_fullStr Balancing the interplay of histone deacetylases and non-coding genomes: a step closer to understand the landscape of cancer treatment
title_full_unstemmed Balancing the interplay of histone deacetylases and non-coding genomes: a step closer to understand the landscape of cancer treatment
title_short Balancing the interplay of histone deacetylases and non-coding genomes: a step closer to understand the landscape of cancer treatment
title_sort balancing the interplay of histone deacetylases and non-coding genomes: a step closer to understand the landscape of cancer treatment
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657130/
https://www.ncbi.nlm.nih.gov/pubmed/37978516
http://dx.doi.org/10.1186/s12920-023-01724-3
work_keys_str_mv AT pujingjing balancingtheinterplayofhistonedeacetylasesandnoncodinggenomesastepclosertounderstandthelandscapeofcancertreatment
AT liuting balancingtheinterplayofhistonedeacetylasesandnoncodinggenomesastepclosertounderstandthelandscapeofcancertreatment
AT sharmaamit balancingtheinterplayofhistonedeacetylasesandnoncodinggenomesastepclosertounderstandthelandscapeofcancertreatment
AT schmidtwolfingogh balancingtheinterplayofhistonedeacetylasesandnoncodinggenomesastepclosertounderstandthelandscapeofcancertreatment

Ejemplares similares